Presentation
The Innovation Department invites you to meet & greet our next invited speaker in the IRB Bridges to Investors, Marc Ramis, Founder & Managing Partner, Montana.
Montana is a venture capital firm born to promote innovative projects in the field of paediatric health.
Marc will share his career and experience in the healthcare and life sciences sector from an investor's point of view, giving insights for researchers.
IRB Bridges to Investors is a meet & greet programme set up by the Innovation Department. It provides participants the opportunity to meet investors in the bio sector and expand and/or consolidate a professional network while understanding how VC world works. Schedule of the session:
Presentation by the Invited Speaker about his career and experience in the healthcare and life sciences sector from an investor's point of view. Presentation of Montana Pediatric Fund.
Q&A session
Closing remarks
Sessions are open to all IRB members (places limited). In addition, a number of places are reserved for IRB Barcelona alumni.
If you wish to participate in this session, please register before 27 February (Registration Form). Alumni should contact us at innovation@irbbarcelona.org.
Speaker: Marc Ramis, Founder & Managing Partner at Montana.
Date: Tuesday, 3 March 2026, 10:00-11:00.
Place: Sala 1 Torres D, Parc Científic de Barcelona (PCB).
Language: English
Audience: Open to the entire IRB Barcelona community (places limited)
Speakers
Marc Ramis, Founder & Managing Partner at Montana.
Marc has a passion for creating novel biomedical ventures.
He is currently dedicated to building companies focused on pediatric innovation. Marc is the Founder and Partner at Montana Children's Health (Ship2B Ventures).Marc co-founded and is a Partner at Chasing Science and Manor House Partners, both early-stage venture builders between London and Barcelona. From England, he also dedicates his time to advising organisations such as Deep Science Ventures and Inside Out. Additionally, he is a Venture Partner at Ship2B Ventures and Korion Life Sciences.
Most recently, Marc served as Co-founder & CEO of Rejuveron Senescence Therapeutics AG, Ninevah Therapeutics Ltd, and Senolytic Therapeutics Inc. He served also as a Board Member or Strategic Advisor for Aptadel Therapeutics, Retinset Therapeutics, Gate2Brain, Dive Medical, Oniria Therapeutics, Nanobots Therapeutics, Cebiotex, Cyclomed, and GeneTether. He was also a founder and advisor at Tech & Business Innovation (TBI), an academic firm specialising in knowledge exchange and corporate-academic partnerships. He has supported investments and strategic partnerships at Life Biosciences Inc. in Europe and has served as an advisor and board member for multiple organisations.
Marc has played a key role in implementing Entrepreneurs-in-Residence programs at institutions such as IRB Barcelona. From 2010 to 2012, he worked with Isis Innovations/University of Oxford as an associate consultant in Spain and LATAM. Earlier, from 2007 to 2011, he was at Endor, a nanomedicine company in Spain, where he served as R&D Director (focusing on drug-delivery nanosystems for cancer therapy) and Business Development Director (launching nanotechnology products for the cosmetic and textile markets).He also has experience in the pharmaceutical industry, having worked at Novartis, and has collaborated with research institutions such as Cancer Research UK and Boston College.
Marc holds a DPhil in Biochemistry from the University of Oxford (2006) and completed the Harvard Business School PLD Program (2011). He also earned an M.Sc. in Chemical Engineering (2001) and a B.Sc. in Chemistry from IQS Barcelona (2000).